H.C. Wainwright analyst Douglas Tsao keeps a Neutral rating on Alkermes (ALKS) with a $46 price target after the company presented detailed Phase 2 data from the Vibrance-1 study after previously announcing the study met its primary endpoint. The quantitative analyses provide incremental confidence in alixorexton’s potential in narcolepsy type 1, but some residual questions remain on improvements in cataplexy and visual side effects, the analyst tells investors in a research note. H.C. Wainwright says Alkermes’ alixorexton outperformed Takeda’s (TAK) oveporexton on the Maintenance of Wakefulness Test, though it oveporexton appeared to have a slight edge on the Epworth Sleepiness Score.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Alkermes Hold Rating: Promising NT1 Data Amidst Competitive and Clinical Challenges
- Cautious Hold Rating on Alkermes Amid Competitive Pressures and Mixed Data for ALKS2680
- Jefferies says stage set for Centessa to differentiate in narcolepsy
- Alkermes narcolepsy data ‘solid,’ about as expected, says Leerink
- Promising Clinical Results and Market Potential Drive Buy Rating for Alkermes